Market Overview

SpinalCyte, LLC Announces New U.S. Patent


SpinalCyte, LLC, a Texas-based regenerative medicine company focused on
regrowth of the spinal disc using Human Dermal Fibroblasts, today
announced issuance of U.S. Patent No. 10,052,410, "Methods and
Compositions For Repair Of Cartilage Using An In Vivo Bioreactor."

The technology described in the patent involves an in vivo
bioreactor which acts as a delivery system to feed and grow cells, like
fibroblasts, and induces cellular differentiation. Additionally, the
device will also be subject to one or more growth factors which may
enhance differentiation of the cells.

"Our patent portfolio uniquely positions us at the forefront of human
dermal fibroblast cell therapy for spinal disc regeneration," said Pete
O'Heeron, Chief Executive Officer, SpinalCyte. "As leaders in this
field, we continue to expand our intellectual property protections."

With this addition, SpinalCyte's portfolio now includes 33 U.S. and
foreign patents issued and 43 patents pending.

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine
company developing an innovative solution for spinal disc regeneration
using human dermal fibroblasts. Currently, SpinalCyte holds 33 U.S. and
international issued patents and has filed for an additional 43 patents
pending. Funded entirely by angel investors, SpinalCyte represents the
next generation of medical advancement in cell therapy. Visit

View Comments and Join the Discussion!